NVAX Stock Up 13%, Novavax Early Trial of COVID-19 Vaccine Shows Stellar Immune Response

Coinspeaker NVAX Stock Up 13%, Novavax Early Trial of COVID-19 Vaccine Shows Stellar Immune ResponseScientists have Novavax's vaccine results to be impressive and exemplary. If the company gets more leads going ahead, it promises of producing 100 million doses by the start of 2021. дальше »